1. Home
  2. EVCM vs GLPG Comparison

EVCM vs GLPG Comparison

Compare EVCM & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EverCommerce Inc.

EVCM

EverCommerce Inc.

HOLD

Current Price

$12.00

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$33.62

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVCM
GLPG
Founded
2006
1999
Country
United States
Belgium
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
EVCM
GLPG
Price
$12.00
$33.62
Analyst Decision
Hold
Hold
Analyst Count
8
4
Target Price
$11.50
$31.33
AVG Volume (30 Days)
275.1K
105.9K
Earning Date
11-06-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$718,038,000.00
$336,643,201.00
Revenue This Year
N/A
$1.76
Revenue Next Year
$5.60
$0.49
P/E Ratio
N/A
N/A
Revenue Growth
22.13
10.31
52 Week Low
$7.66
$22.36
52 Week High
$14.41
$37.78

Technical Indicators

Market Signals
Indicator
EVCM
GLPG
Relative Strength Index (RSI) 56.25 64.63
Support Level $11.63 $32.39
Resistance Level $12.45 $33.27
Average True Range (ATR) 0.48 0.67
MACD -0.10 0.05
Stochastic Oscillator 70.06 85.45

Price Performance

Historical Comparison
EVCM
GLPG

About EVCM EverCommerce Inc.

EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: